

Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)

Blocklisting Six Monthly Return

London: Monday, 1 July 2013: Chi-Med announces the following blocklisting six monthly return:

Hutchison China MediTech Limited 1. Name of applicant: 2. Name of scheme: Hutchison China MediTech Limited Share Option Scheme From 29 December 2012 to 28 June 2013 3. Period of return: 4. Balance under scheme from previous 1,724,279 ordinary shares of US\$1 each return: The amount by which the block scheme Nil has been increased, if the scheme has been increased since the date of the last return: Number of securities issued/allotted 3,000 ordinary shares of US\$1 each under scheme during period: Balance under scheme not yet 1,721,279 ordinary shares of US\$1 each issued/allotted at end of the period: Number and class of securities originally 2,560,606 ordinary shares of US\$1 each 8. listed and the date of admission: admitted on 26 June 2007 Total number of securities in issue at the 52,051,448 ordinary shares of US\$1 each end of the period: Name of contact: Christian Hogg Address of contact: 21/F., Hutchison House, 10 Harcourt Road, Hong Kong Telephone number of contact: +852 2121 8200

Ends

Enquiries

Chi-Med Telephone: +852 2121 8200

Christian Hogg, CEO

Panmure Gordon (UK) Limited Telephone: +44 20 7886 2500

Richard Gray Andrew Potts Grishma Patel

 Citigate Dewe Rogerson
 Telephone:
 +44 20 7638 9571

 Anthony Carlisle
 Mobile:
 +44 7973 611 888

 David Dible
 Mobile:
 +44 7967 566 919

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.